Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 7/20 | 1.00 |
| ▸ | CCR1 | P32246 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18840724 | 0.88 | CCR3 (1.00) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL5489840 | 0.86 | CCR3 (1.00) | CCR3CCR1NPC1RAB9ASIGMAR1 | |
| SCHEMBL18840726 | 0.84 | CCR3 (1.00) | CCR3CCR1SIGMAR1ALDH1A1MEN1 | |
| SCHEMBL18844210 | 0.83 | CCR3 (0.88) | CCR3CCR1NPC1RAB9ASIGMAR1 | |
| SCHEMBL14454576 | 0.81 | CCR3 (0.87) | CCR3CCR1NPC1RAB9ASIGMAR1 | |
| SCHEMBL2212518 | 0.79 | CCR3 (0.70) | CCR3CCR1SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL4034267 | 0.76 | CCR3 (0.84) | CCR3CCR1SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4203425 | 0.76 | CCR3 (0.61) | CCR3CCR1NPC1SIGMAR1ALDH1A1 | |
| SCHEMBL18840703 | 0.76 | CCR3 (1.00) | CCR3CCR1SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4030905 | 0.75 | CCR3 (0.64) | CCR3CCR1NPC1SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | CCR3 1/4885CCR1 3/4885NPC1 2003/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | CCR3 1/4885CCR1 3/4885NPC1 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.